Preview

January 2020

In the next issue of Pharma Technology Focus, we delve into the biggest topics set to influence the global market in 2020 and beyond. But first, we take a look back at the development of breast cancer treatment following the news that the number of cancer deaths has declined by almost 50% since the 1980s.

Looking forward, we investigate why access to PrEp drugs in England is restricted to patients in the NHS Impact trial despite the proven efficacy of the treatment, ask if Big Pharma can be taxed into putting patients before profits, and find out how companies are addressing the burden of endometriosis.

Plus, we track the rise of fake medications in Africa, examine a CAR-T therapy that protects non-diseased T cells, explore how 2019 Nobel Prize-winning research into how oxygen levels affect cellular metabolism and physiological function will change drug discovery, and finally, we look to the East to find out what is next for China’s surging market.

EDITORIAL

Editor | Eloise McLennan

Group Editor | Susanne Hauner

Commissioning Editor| Daniel Garrun

Writers | Allie Nawrat, Abi Millar, Chris Lo
Magazine Designer | Marzia Del Gaone

Graphic Designers | Anett Arc, Ashley McPherson, Tyrrell Lowe, Noemi Balint, Petra Konyi-Kiss, Maria Gimenez, Martina Labaiova, Filipe Costa
Lead Designer | John Hammond 
Digital Publishing Director | Duncan West

Advertising

Sales Manager | Nimai Amin

+44 (0) 207 936 6453

Marketing

For media partnership enquiries please contact our publishing assistant: Sophie Hoare

Pharma Technology focus is powered by h5mag

read past issues of pharma technology focus HERE

Pharma Technology Focus is a product of Net Resources International. Copyright 2019 Net Resources International, a trading division of Kable Intelligence Limited. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.

Go to article: Home | Saving face: PR in pharma Go to article: In this issueGo to article: Emirates SkyCargoGo to article: ContentsGo to article: Hapa Company Insight Go to article: Owen MumfordGo to article: NewsGo to article: Dupont PharmaceuticalsGo to article: Accurate Biometrics Company Insight Go to article: Accurate BiometricsGo to article: The pharma industry briefingGo to article: Scandinavian Health Ltd.Go to article: Gerteis Company InsightGo to article: GerteisGo to article: Coughs and sneezes spread diseases: charting the development of flu vaccinesGo to article: Swiss WorldCargoGo to article: HOF Sonderanlagenbau Company Insight Go to article: HOF SonderanlagenbauGo to article: ‘Don’t put baby in the corner’: overcoming challenges in paediatric drug developmentGo to article: Qatar AirwaysGo to article: AtoZ-CRO Company InsightGo to article: AtoZ-CROGo to article: Debate: should countries bring critical drug production home?Go to article: AirBridgeCargo Company InsightGo to article: AirBridgeCargoGo to article: Capsugel Company Insight Go to article: Beyond Viagra Town: profiling the Irish pharma industryGo to article: Daiichi JitsugyoGo to article: TSS Company Insight Go to article: TSSGo to article: Recurrent miscarriage: could this devastating condition have a simple cure?Go to article: LB Bohle Company Insight Go to article: LB BohleGo to article: Public image limited: the role of PR in pharmaGo to article: Pharma Support Services Company InsightGo to article: Pharma Support ServicesGo to article: Q&A: Gavi alliance talks immunising 300 million people Go to article: Spirax Sarco Company Insight Go to article: Spirax SarcoGo to article: Bias remorse: are cancer drug trials clear enough on outcomes?Go to article: Zenatek Go to article: B&W TekGo to article: Deals in brief powered by GlobalDataGo to article: Centaur Clinical Insight Go to article: Centaur ClinicalGo to article: The key list powered by GlobalDataGo to article: AlpexGo to article: PfanstiehlGo to article: EventsGo to article: MimotopesGo to article: NymiGo to article: Next issue